Pivotal data for the novel KRAS G12C inhibitor glecirasib have been presented at the April ASCO Plenary Series.
Developed by Hong Kong-listed Jacobio Pharma (HKG: 1167), glecirasib is being tested for the second-line treatment of non-small cell lung cancer (NSCLC).
The firm hopes to be able to provide a safer and more effective option than chemotherapy, which remains the main second-line option for many people with this kind of lung cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze